Description
Anti-S100 calcium binding protein B Antibody, Non-Fucosylated (BioBet-1260ZP) is a humanized monoclonal IgG antibody against S100 calcium binding protein B. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Respiratory Diseases
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced S100 calcium binding protein B antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
S100B
Full Name
S100 calcium binding protein B
Background
The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21; however, this gene is located at 21q22.3. This protein may function in Neurite extension, proliferation of melanoma cells, stimulation of Ca2+ fluxes, inhibition of PKC-mediated phosphorylation, astrocytosis and axonal proliferation, and inhibition of microtubule assembly. Chromosomal rearrangements and altered expression of this gene have been implicated in several neurological, neoplastic, and other types of diseases, including Alzheimers disease, Downs syndrome, epilepsy, amyotrophic lateral sclerosis, melanoma, and type I diabetes.
Alternative Names
S100B; S100 calcium binding protein B; NEF; S100; S100-B; S100beta; protein S100-B; S-100 protein subunit beta; S-100 calcium-binding protein, beta chain; S100 calcium-binding protein, beta (neural)
Gene ID
6285
Cellular Localization
Nucleus
Involvement in Disease
Diseases associated with S100B include Malignant Peripheral Nerve Sheath Tumor and Neurofibroma.
Related Pathways
Its related pathways are Neuroscience and Signaling by GPCR.
Function
The binding to calcium is weak, but the binding to zinc is very tight-the two ions have different affinity binding sites on each monomer. Physiological concentration of potassium ions antagonizes the combination of two divalent cations, especially the high-affinity calcium binding site. It binds and initiates the activation of STK38 through intramolecular interactions released from inhibition within the kinase. The interaction with AGER after myocardial infarction may participate in cardiomyocyte apoptosis by activating ERK1/2 and p53/TP53 signaling pathways. It can assist ATAD3A cytoplasmic processing, prevent aggregation, and facilitate mitochondrial positioning. It is possible to regulate calcium-dependent regulation in many physiological processes by interacting with other proteins (such as tpr-containing proteins) and regulating their activities.
Field of research
Cell Biology and Cellular Response antibody; Developmental Biology antibody; Gene Regulation antibody
Post-translational modifications
1.Modification sites at neXtProt 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1260ZP
Description
The anti-S100B antibody are used in a method for reducing airway hyper-response . Airway hyper-response ("AHR") is a characteristic feature of many airway diseases and consists of an abnormality of the airways that allows them to narrow too easily and/or too much in response to a stimulus. Respiratory diseases, associated with a variety of conditions, are extremely common in the general population. Airway hyperresponse is observed in particular in asthma and chronic obstructive pulmonary disease (COPD).
Antibody Indication
Respiratory Diseases
